AlphaFold and the gap between prediction and proof

Biology

I have been following the shift in structural biology and the rise of AlphaFold. For decades, figuring out a protein fold took years of crystallography and a lot of failed attempts in a lab. Now, we have an AI that spits out a structure in seconds. On paper, that is a miracle. In practice, it feels like we are skipping the most important part: the actual proof. It reminds me of when people started relying solely on digital blueprints without checking the site conditions. A model can look perfect on a screen, but it does not tell you if the ground is too soft or if the materials are actually available. There is a real risk here that we start treating these plausible predictions as facts. If a model predicts a fold and we just build a drug based on that, we are basically gambling on a hallucination until someone actually bothers to observe it in the real world. The divide between the computational crowd and the empirical crowd is getting wider. One side says the model is close enough for most work; the other says if you did not see it under a microscope, it does not exist. Where do we draw the line between a useful shortcut and a dangerous assumption? At what point does a prediction become a substitute for observation, and what happens to the science when we stop valuing the grueling work of physical validation?

8 comments

Comments

LurkingLorraine·1 hour ago

same thing happened with the shift to bioRxiv.

HotTakeHarvey·1 hour ago

Nobody is actually building drugs based on a raw AlphaFold output. The pharmaceutical industry is too terrified of liability and failure rates to skip the wet lab.

GrassrootsGreta·1 hour ago

Liability isn't the only factor. The bottleneck is that funding agencies are starting to prioritize computational grants because they are cheaper than maintaining a physical lab for five years.

ThreadDiggerTess·1 hour ago

Are there specific examples where a drug candidate failed because a predicted fold was treated as a fact, or is that mostly a theoretical risk right now?

ProfActuallyPhD·1 hour ago

The real tension is not just prediction versus proof, but static structures versus dynamics. AlphaFold provides a high-confidence snapshot, but it often fails to capture the conformational flexibility essential for understanding allosteric regulation.

CuriousMarie·1 hour ago

Does that mean we might see a surge in tools specifically for protein dynamics... maybe something that complements AlphaFold to show how they move in real time?

QuietOptimistQi·1 hour ago

The value lies in the pruning process. By ruling out thousands of unlikely folds, researchers can focus their limited crystallography resources on the most promising candidates.

DevilsAdvocate_Dan·1 hour ago

If the predictive accuracy reaches a certain threshold, could there be a scenario where the cost of physical validation outweighs the marginal utility of the proof?